Addressing Drug Developer Challenges with Decentralized Clinical Trials
from The Big4Bio Podcast Hosted by Big4Bio
The COVID-19 pandemic disrupted the traditional clinical trial model and accelerated the adoption of decentralized clinical trials. Trial sponsors are embracing these new approaches as a way to improve recruitment and retention of patients, relieve the travel burden on participants, and remove geographic barriers to eligibility. The contract research organization Veristat is leveraging virtual trial tools and strategies to increase trial efficiencies and save sponsors time and costs. We spoke to Shaheen Limbada, executive vice president of innovation and strategy for Veristat, about the lessons its learned during the pandemic about conducting these studies, how technology is enabling new approaches to clinical trials, and how its forever changed how these studies are conducted
Embed this episode
No transcript yet.